- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06641635
Radioterapia adattiva online ipofrazionata moderata nel cancro della cervice
Uno studio multicentrico, di non inferiorità, di fase 3, randomizzato e controllato sulla radioterapia adattiva online ipofrazionata moderata per il cancro della cervice
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This is a multicenter, non-inferiority, phase 3, randomized controlled study. This study investigates the role of moderated hypofractionated online adaptive radiotherapy by randomizing patients to this experimental regimen versus the standard of treatment.The purpose of this study is to access safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with high-dose-rate brachytherapy in patients with cervical cancer, which based on the previous research (NCT05994300).
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Zheng Zeng, MD.
- Numero di telefono: 86-10-6512-4875
- Email: zengzheng1206@163.com
Luoghi di studio
-
-
-
Beijing, Cina
- Reclutamento
- Peking Union Medical College Hospital
-
Contatto:
- Junfang Yan, MD
- Numero di telefono: 01069155484
- Email: yanjunfang@pumch.cn
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment
- Age ≥18 and ≤75 years
- FIGO 2018 stage IB1-IIB, IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis)
- Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Concurrent weekly cisplatin therapy ± immunotherapy
- Able to undergo brachytherapy
- ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.
Exclusion Criteria:
- Patients who have undergone cervical cancer surgery
- FIGO stages IA, IIIA, IIIC2, IVA, or IVB
- FIGO stage IIIC1 with lymph nodes >2 cm, or with common iliac lymph node metastasis
- Patients who received other anticancer treatments, including chemotherapy, targeted therapy, or immunotherapy, before concurrent chemoradiotherapy.
- History of prior abdominal or pelvic radiotherapy
- Pregnant or breastfeeding women
- Patients with active infections or fever
- Other severe diseases that may significantly affect clinical trial compliance, such as unstable heart disease, kidney disease, chronic hepatitis requiring treatment, poorly controlled diabetes, or mental disorders.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental group
Moderately hypofractionated online adaptive radiotherapy +Concurrent Chemotherapy or Immunotherapy Experimental |
Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy Drug: Concurrent Chemotherapy or immunotherapy Weekly cisplatin 40 mg/m2 or PD-1 inhibitors |
|
Comparatore attivo: Control group
Conventionally fractionated intensity-modulated radiotherapy +Concurrent Chemotherapy or Immunotherapy Standard of Care |
Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Contral group: 45Gy/25F EBRT + HDR-Brachytherapy Drug: Concurrent Chemotherapy or immunotherapy Weekly cisplatin 40 mg/m2 or PD-1 inhibitors |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression Free Survival
Lasso di tempo: 3 years
|
Defined as time from date of randomization to date of progression, date of death from any cause, or date of last follow-up, whichever occurs first. Cancer progression can be identified during physical exam, biopsy, or imaging of any kind. |
3 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Acute toxicity
Lasso di tempo: 3 months
|
This outcome is assessed by physicians during each follow-up appointment, and scored according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 . Clinically relevant toxicities of gastrointestinal, genitourinary, vaginal and non-specific general symptoms (i.e. fatigue, malaise and pain) will be collected. Hematological disorders will also be collected through weekly blood work checks. Acute toxicities will be collected at baseline, and then weekly during radiotherapy/chemoradiotherapy and at 3 months after completion of radiation. |
3 months
|
|
Late toxicity
Lasso di tempo: 3 years
|
Late toxicities will be collected from 3 months after completion of radiation onwards until the end of follow-up. |
3 years
|
|
Overall survival
Lasso di tempo: 3 years
|
Defined as time from date of randomization to date of death from any cause, or date of last follow-up, whichever occurs first. |
3 years
|
|
Quality of life (QoL)
Lasso di tempo: 3 years
|
QoL will evaluated by the EORTC QLQ-C30 questionnaire.QLQ-C30 questionnaire is used for all cancers and has several symptom scales, five functional scales (physical, emotional, social, role, cognitive) and a global health status scale. Response options are a four-point Likert scale from "not at all" to "very much" or a seven-point Likert scale from "very poor" to "excellent." |
3 years
|
|
Quality of Life (QoL)
Lasso di tempo: 3 years
|
QoL will be measured by the cervical cancer module (QLQ-CX24). QLQ-CX24 includes cancer - and treatment - related items and symptoms regarding sexuality. Acute and late vaginal and sexual QoL will be assessed using the QLQ-CX24 vaginal and sexual domains respectively. The QLQ-CX24 responses are regarding function and symptoms of sexual and vagina health. It is based on a scale of 1 (not at all) to 4 (very much). |
3 years
|
|
Locoregional progression-free survival
Lasso di tempo: 3 years
|
Defined as time from date of randomization to date of locoregional progression, date of death from any cause, or date of last follow-up, whichever occurs first. |
3 years
|
|
Tumor response evaluation Complete remission rate
Lasso di tempo: 3 months
|
Evaluated with RECIST 1.1 |
3 months
|
|
Metastasis-free survival
Lasso di tempo: 3 years
|
Defined as time from date of randomization to date of development of metastasis, date of death from any cause, or date of last follow-up, whichever occurs first. |
3 years
|
|
Cervical cancer-specific survival
Lasso di tempo: 3 years
|
Defined as time from date of randomization to date of death attributed to cervical cancer, or date of last-follow-up, whichever occurs first. |
3 years
|
|
Treatment expense
Lasso di tempo: 3 months
|
The treatment-related costs incurred during the course of treatment. |
3 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assessment of tumor regression throughout EBRT
Lasso di tempo: 3 months
|
To be assessed through volumetric comparison of tumor volume in the pre-EBRT and post-EBRT MRI scans. |
3 months
|
Collaboratori e investigatori
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie uterine
- Malattie genitali, femmina
- Neoplasie genitali, femmina
- Malattie della cervice uterina
- Neoplasie uterine
- Neoplasie cervicali uterine
Altri numeri di identificazione dello studio
- SWIFT-1
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .